MJP Associates’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$210K Buy
2,628
+180
+7% +$14.8K 0.03% 218
2025
Q4
$209K Buy
+2,448
New +$201K 0.03% 234
2024
Q3
Sell
-8,590
Closed -$793K 227
2024
Q2
$793K Buy
8,590
+340
+4% +$30.1K 0.17% 69
2024
Q1
$788K Buy
8,250
+2,075
+34% +$174K 0.17% 72
2023
Q4
$471K Buy
6,175
+83
+1% +$5.78K 0.13% 82
2023
Q3
$422K Buy
6,092
+295
+5% +$23.7K 0.12% 78
2023
Q2
$547K Buy
5,797
+763
+15% +$66.3K 0.18% 70
2023
Q1
$416K Buy
5,034
+329
+7% +$25.9K 0.13% 76
2022
Q4
$351K Buy
4,705
+171
+4% +$13.2K 0.1% 90
2022
Q3
$375K Sell
4,534
-116
-2% -$11.2K 0.11% 82
2022
Q2
$442K Sell
4,650
-339
-7% -$35.1K 0.12% 72
2022
Q1
$587K Sell
4,989
-409
-8% -$45.9K 0.15% 68
2021
Q4
$693K Buy
5,398
+921
+21% +$107K 0.21% 66
2021
Q3
$507K Buy
4,477
+55
+1% +$6.28K 0.17% 72
2021
Q2
$458K Sell
4,422
-42
-0.9% -$3.96K 0.15% 77
2021
Q1
$373K Buy
4,464
+377
+9% +$31.9K 0.15% 82
2020
Q4
$373K Buy
+4,087
New +$339K 0.16% 79

Other funds holding EW

MJP Associates's EW Position: Q1 2026 in Review

MJP Associates increased its Edwards Lifesciences (EW) stake by 7.4% in Q1 2026, buying an estimated $14.8K and bringing the position to 2,628 shares worth $210K. The position accounts for 0.03% of the portfolio, ranked #218.

MJP Associates first reported a position in EW in Q4 2020 and has held it in 17 quarters since. The position peaked at $793K in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • MJP Associates held 2,628 shares of Edwards Lifesciences worth $210K as of Q1 2026.
  • MJP Associates bought 180 Edwards Lifesciences shares in Q1 2026, an estimated $14.8K.
  • Edwards Lifesciences made up 0.03% of MJP Associates's portfolio in Q1 2026, its #218 holding.
  • MJP Associates first reported a position in Edwards Lifesciences in Q4 2020 and has held it in 17 quarters since.
  • MJP Associates's Edwards Lifesciences position peaked at $793K in Q2 2024.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on MJP Associates's 13F filing for Q1 2026, filed 5 May 2026.